GW Pharmaceuticals (GWPH) Ahead of Earnings; Tiger Management Bets On Enzymotec (ENZY)


GW Pharmaceuticals plc (Nasdaq:GWPH) stock closed at $83.59, down $2.27 (or -2.64%), and 394,941 of its shares exchanged hands on Friday’s trading session

The company expects to release its quarterly earnings report on Monday after the closing bell, which would include newly available data related to Epidiolex, its investigational drug for the treatment of various orphan pediatric epilepsy syndromes

GW Pharmaceuticals, a biopharmaceutical company developing a portfolio of cannabinoid medicines, has 20.89M Shares Outstanding, Market Capitalization (intraday) of $1.75B and GWPH stock 52-week range is from $65.28 to $133.98 per share



Tiger Management L.L.C. disclosed in a regulatory filing ( SC 13G ) with the U.S. Securities and Exchange Commission (SEC) a 5.2% passive stake (1,162,845 shares) in Enzymotec Ltd. (Nasdaq:ENZY)

Enzymotec recently reported third quarter 2015 revenue of $12.4 million, a 30.7% increase year over year, and non-GAAP net income of $2.0 million, or $0.08 per diluted share, increased 32.9% versus the same period the prior year

ENZY stock finished at $9.89, up $0.10 (or +1.02%) on Friday’s market activity, with a total volume of 20,930 shares traded during the day

Enzymotec, which develops and manufactures nutritional ingredients and medical foods, has 22.48M Shares Outstanding, Market Capitalization (intraday) of $222.36M and ENZY stock one-year range is between $5.38 and $10.83 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at